Impact Therap-b (7630) Fundamentals 2026 — Revenue Analysis | SniperIQ
Impact Therap-b (7630) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK
Impact Therap-b (7630) has a market capitalization of approximately HK
Impact Therap-b runs a net profit margin of -778.4%, a gross margin of 84.1%, and an operating margin of -605.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Impact Therap-b reported revenue of $5M for fiscal year 2025, with net income of -$41M and earnings per share (EPS) of -0.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Impact Therap-b does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Impact Therap-b carries a debt-to-equity ratio of -0.90x and a current ratio of 3.08x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Impact Therap-b (7630) the key facts are: market cap HK
Get Impact Therap-b's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.